Zobrazeno 1 - 10 of 60 pro vyhledávání: '"R B, Diasio"'
3
Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation
Autor: Avi I. Einzig, E. L. Schwartz, Peter H. Wiernik, Scott Wadler, Zhihang Lu, R. B. Diasio, Ruiwen Zhang, Joseph A. Sparano
Publikováno v: Journal of Clinical Oncology. 11:1609-1617
PURPOSE To determine the maximum-tolerable dose (MTD) of fluorouracil (5-FU) administered as a low-dose, prolonged continuous intravenous infusion (PCI) plus interferon-alfa (IFN-alpha) that would permit treatment for at least 28 consecutive days, an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::836397fcdec86894f416d24c786a96e0
https://doi.org/10.1200/jco.1993.11.8.1609
Zobrazit plný text záznamu
4
Abstracts of oral presentations
Autor: R. Boulieu, A. Lenoir, J. F. Mornex, C. Bohman, J. Balzarini, P. Wigerinck, A. Aerschot, P. Herdewijn, Erik Clercq, S. Brosh, E. Zoref-Shani, O. Sperling, E. Danziger, Y. Sidi, Y. Bromberg, Renate Burgemeister, Elke Rötzer, Wolf Gutensohn, G. P. Connolly, P. J. Harrison, R. B. Diasio, Z. Lu, R. Zhang, U. Gresser, W. Gutensohn, R. Resta, L. F. Thompson, F. Javaux, M. F. Vincent, G. Berghe, I. Kamilli, R. Rauch, D. Hahn, C. W. Keuzenkamp-Jansen, R. A. Abreu, J. P. M. Bökkerink, M. A. H. Heijden, M. Löffler, C. Becker, E. Wegerie, M. Marcussen, K. Overgaard-Hansen, H. Klenow, A. M. Marinaki, E. H. Harley, M. B. McBride, H. A. Simmonds, F. Moro, J. S. Cameron, C. S. Ogg, D. G. Williams, S. Rigden, G. Haycock, M. E. Miranda, J. G. Puig, F. A. Mateos, J. O. Vázquez, V. W. T. Ruiz Haperen, G. Veerman, J. B. Vermorken, G. J. Peters, C. L. Wilt, P. Noordhuis, K. Smid, H. M. Pinedo, C. Salerno, A. Lomonte, O. Giardini, C. Crifo, R. T. Smolenski, M. H. Yacoub, A. M. -L. Seymour, A. P. A. Stegmann, M. W. Honders, R. Willemze, J. E. Landegent, E. H. Stet, G. M. Vogels-Mentink, L. H. J. Lambooy, J. M. F. Trijbels, R. J. Torres, M. G. Tozzi, R. Pesi, M. Turriani, S. Allegrini, M. Camici, P. L. Ipata, A. A. Berg, J. R. Meinsma, H. Lenthe, A. H. Gennip, A. B. P. Kuilenburg, N. G. G. M. Abeling, H. D. Bakker, R. J. Slingerland, F. Bergh, R. L. Sabina
Publikováno v: Pharmacy World & Science. 15:F7-F14
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::998f79b3fc5c41061e4d3e16542225b7
https://doi.org/10.1007/bf02297670
Zobrazit plný text záznamu
5
Current status of oral chemotherapy for colorectal cancer
Autor: R B, Diasio
Publikováno v: Oncology (Williston Park, N.Y.). 15(3 Suppl 5)
The treatment of advanced colorectal cancer over the past 4 decades has required the use of intravenous chemotherapy, most typically fluorouracil (5-FU). The possibility of providing an alternative to intravenous delivery while at the same time impro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::47b35a566ec907e026ab957274870a69
https://pubmed.ncbi.nlm.nih.gov/11301835
Zobrazit plný text záznamu
6
Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology
Autor: R B, Diasio
Publikováno v: Oncology (Williston Park, N.Y.). 15(1 Suppl 2)
Dihydropyrimidine dehydrogenase (DPD) is the initial rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), accounting for catabolism of over 85% of an administered dose of 5-FU. DPD plays an important role in regulating the availability of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1d7be02142efa39ee070ef885c8b5d53
https://pubmed.ncbi.nlm.nih.gov/11219973
Zobrazit plný text záznamu
7
Oral DPD-inhibitory fluoropyrimidine drugs
Autor: R B, Diasio
Publikováno v: Oncology (Williston Park, N.Y.). 14(10 Suppl 9)
Over the past decade, increasing data have emphasized both the importance of dihydropyrimidine dehydrogenase (DPD), the initial, rate-limiting enzyme in the catabolism of fluorouracil (5-FU), and its role as a control step in 5-FU metabolism, regulat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b4b25961f537252899ebc2143a803540
https://pubmed.ncbi.nlm.nih.gov/11098485
Zobrazit plný text záznamu
8
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
Autor: D, Salonga, K D, Danenberg, M, Johnson, R, Metzger, S, Groshen, D D, Tsao-Wei, H J, Lenz, C G, Leichman, L, Leichman, R B, Diasio, P V, Danenberg
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 6(4)
We had previously shown that high gene expressions (mRNA levels) of thymidylate synthase (TS; Leichman et al., J. Clin. Oncol., 15: 3223-3229, 1997) and thymidine phosphorylase (TP; Metzger et al., Clin. Cancer Res., 4: 2371-2376, 1998) in pretreatme
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c9a1c74d8873c044601f2b9b6a92d2c6
https://pubmed.ncbi.nlm.nih.gov/10778957
Zobrazit plný text záznamu
10
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil
Autor: M R, Johnson, A, Hageboutros, K, Wang, L, High, J B, Smith, R B, Diasio
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5(8)
In humans, 80-90% of an administered dose of 5-fluorouracil (5-FU) is degraded by dihydropyrimidine dehydrogenase (DPD; EC 1.3.1.2), the initial rate-limiting enzyme in pyrimidine catabolism. Cancer patients with decreased DPD activity are at increas
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ff678f44e784b6409a9089d41073d37d
https://pubmed.ncbi.nlm.nih.gov/10473070
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje